• Resources
  • Blog
  • Journalists
  • Log In
  • Sign Up
  • Data Privacy
  • Send a Release
Cision PR Newswire: news distribution, targeting and monitoring home
  • News
  • Products
    • Overview
    • Distribution by PR Newswire
    • Cision Communications Cloud®
    • Cision IR
    • Sponsored Placement
    • All Products
  • Contact
    • General Inquiries
    • Request a Demo
    • Editorial Bureaus
    • Partnerships
    • Media Inquiries
    • Worldwide Offices

 

When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News in Focus
      • Browse News Releases

      • All News Releases
      • All Public Company
      • English-only
      • News Releases Overview

      • Multimedia Gallery

      • All Multimedia
      • All Photos
      • All Videos
      • Multimedia Gallery Overview

      • Trending Topics

      • All Trending Topics
  • Business & Money
      • Auto & Transportation

      • All Automotive & Transportation
      • Aerospace, Defense
      • Air Freight
      • Airlines & Aviation
      • Automotive
      • Maritime & Shipbuilding
      • Railroads and Intermodal Transportation
      • Supply Chain/Logistics
      • Transportation, Trucking & Railroad
      • Travel
      • Trucking and Road Transportation
      • Auto & Transportation Overview

      • View All Auto & Transportation

      • Business Technology

      • All Business Technology
      • Blockchain
      • Broadcast Tech
      • Computer & Electronics
      • Computer Hardware
      • Computer Software
      • Data Analytics
      • Electronic Commerce
      • Electronic Components
      • Electronic Design Automation
      • Financial Technology
      • High Tech Security
      • Internet Technology
      • Nanotechnology
      • Networks
      • Peripherals
      • Semiconductors
      • Business Technology Overview

      • View All Business Technology

      • Entertain­ment & Media

      • All Entertain­ment & Media
      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • Entertain­ment & Media Overview

      • View All Entertain­ment & Media

      • Financial Services & Investing

      • All Financial Services & Investing
      • Accounting News & Issues
      • Acquisitions, Mergers and Takeovers
      • Banking & Financial Services
      • Bankruptcy
      • Bond & Stock Ratings
      • Conference Call Announcements
      • Contracts
      • Cryptocurrency
      • Dividends
      • Earnings
      • Earnings Forecasts & Projections
      • Financing Agreements
      • Insurance
      • Investments Opinions
      • Joint Ventures
      • Mutual Funds
      • Private Placement
      • Real Estate
      • Restructuring & Recapitalization
      • Sales Reports
      • Shareholder Activism
      • Shareholder Meetings
      • Stock Offering
      • Stock Split
      • Venture Capital
      • Financial Services & Investing Overview

      • View All Financial Services & Investing

      • General Business

      • All General Business
      • Awards
      • Commercial Real Estate
      • Corporate Expansion
      • Earnings
      • Environmental, Social and Governance (ESG)
      • Human Resource & Workforce Management
      • Licensing
      • New Products & Services
      • Obituaries
      • Outsourcing Businesses
      • Overseas Real Estate (non-US)
      • Personnel Announcements
      • Real Estate Transactions
      • Residential Real Estate
      • Small Business Services
      • Socially Responsible Investing
      • Surveys, Polls and Research
      • Trade Show News
      • General Business Overview

      • View All General Business

  • Science & Tech
      • Consumer Technology

      • All Consumer Technology
      • Artificial Intelligence
      • Blockchain
      • Cloud Computing/Internet of Things
      • Computer Electronics
      • Computer Hardware
      • Computer Software
      • Consumer Electronics
      • Cryptocurrency
      • Data Analytics
      • Electronic Commerce
      • Electronic Gaming
      • Financial Technology
      • Mobile Entertainment
      • Multimedia & Internet
      • Peripherals
      • Social Media
      • STEM (Science, Tech, Engineering, Math)
      • Supply Chain/Logistics
      • Wireless Communications
      • Consumer Technology Overview

      • View All Consumer Technology

      • Energy & Natural Resources

      • All Energy
      • Alternative Energies
      • Chemical
      • Electrical Utilities
      • Gas
      • General Manufacturing
      • Mining
      • Mining & Metals
      • Oil & Energy
      • Oil and Gas Discoveries
      • Utilities
      • Water Utilities
      • Energy & Natural Resources Overview

      • View All Energy & Natural Resources

      • Environ­ment

      • All Environ­ment
      • Conservation & Recycling
      • Environmental Issues
      • Environmental Policy
      • Environmental Products & Services
      • Green Technology
      • Natural Disasters
      • Environ­ment Overview

      • View All Environ­ment

      • Heavy Industry & Manufacturing

      • All Heavy Industry & Manufacturing
      • Aerospace & Defense
      • Agriculture
      • Chemical
      • Construction & Building
      • General Manufacturing
      • HVAC (Heating, Ventilation and Air-Conditioning)
      • Machinery
      • Machine Tools, Metalworking and Metallurgy
      • Mining
      • Mining & Metals
      • Paper, Forest Products & Containers
      • Precious Metals
      • Textiles
      • Tobacco
      • Heavy Industry & Manufacturing Overview

      • View All Heavy Industry & Manufacturing

      • Telecomm­unications

      • All Telecomm­unications
      • Carriers and Services
      • Mobile Entertainment
      • Networks
      • Peripherals
      • Telecommunications Equipment
      • Telecommunications Industry
      • VoIP (Voice over Internet Protocol)
      • Wireless Communications
      • Telecomm­unications Overview

      • View All Telecomm­unications

  • Lifestyle & Health
      • Consumer Products & Retail

      • All Consumer Products & Retail
      • Animals & Pets
      • Beers, Wines and Spirits
      • Beverages
      • Bridal Services
      • Cannabis
      • Cosmetics and Personal Care
      • Fashion
      • Food & Beverages
      • Furniture and Furnishings
      • Home Improvement
      • Household, Consumer & Cosmetics
      • Household Products
      • Jewelry
      • Non-Alcoholic Beverages
      • Office Products
      • Organic Food
      • Product Recalls
      • Restaurants
      • Retail
      • Supermarkets
      • Toys
      • Consumer Products & Retail Overview

      • View All Consumer Products & Retail

      • Entertain­ment & Media

      • All Entertain­ment & Media
      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • Entertain­ment & Media Overview

      • View All Entertain­ment & Media

      • Health

      • All Health
      • Biometrics
      • Biotechnology
      • Clinical Trials & Medical Discoveries
      • Dentistry
      • FDA Approval
      • Fitness/Wellness
      • Health Care & Hospitals
      • Health Insurance
      • Infection Control
      • International Medical Approval
      • Medical Equipment
      • Medical Pharmaceuticals
      • Mental Health
      • Pharmaceuticals
      • Supplementary Medicine
      • Health Overview

      • View All Health

      • Sports

      • All Sports
      • General Sports
      • Outdoors, Camping & Hiking
      • Sporting Events
      • Sports Equipment & Accessories
      • Sports Overview

      • View All Sports

      • Travel

      • All Travel
      • Amusement Parks and Tourist Attractions
      • Gambling & Casinos
      • Hotels and Resorts
      • Leisure & Tourism
      • Outdoors, Camping & Hiking
      • Passenger Aviation
      • Travel Industry
      • Travel Overview

      • View All Travel

  • Policy & Public Interest
      • Policy & Public Interest

      • All Policy & Public Interest
      • Advocacy Group Opinion
      • Animal Welfare
      • Congressional & Presidential Campaigns
      • Corporate Social Responsibility
      • Domestic Policy
      • Economic News, Trends, Analysis
      • Education
      • Environmental
      • European Government
      • FDA Approval
      • Federal and State Legislation
      • Federal Executive Branch & Agency
      • Foreign Policy & International Affairs
      • Homeland Security
      • Labor & Union
      • Legal Issues
      • Natural Disasters
      • Not For Profit
      • Patent Law
      • Public Safety
      • Trade Policy
      • U.S. State Policy
      • Policy & Public Interest Overview

      • View All Policy & Public Interest

  • People & Culture
      • People & Culture

      • All People & Culture
      • Aboriginal, First Nations & Native American
      • African American
      • Asian American
      • Children
      • Diversity, Equity & Inclusion
      • Hispanic
      • Lesbian, Gay & Bisexual
      • Men's Interest
      • People with Disabilities
      • Religion
      • Senior Citizens
      • Veterans
      • Women
      • People & Culture Overview

      • View All People & Culture

      • In-Language News

      • español
      • português
      • Česko
      • Danmark
      • Deutschland
      • España
      • France
      • Italia
      • Nederland
      • Norge
      • Polska
      • Portugal
      • Россия
      • Slovensko
      • Suomi
      • Sverige
  • Overview
  • Distribution by PR Newswire
  • Cision Communications Cloud®
  • Cision IR
  • Sponsored Placement
  • All Products
  • General Inquiries
  • Request a Demo
  • Editorial Bureaus
  • Partnerships
  • Media Inquiries
  • Worldwide Offices
  • PR Newswire: news distribution, targeting and monitoring
  • Send a Release
    • ALL CONTACT INFO
    • Contact Us

      888-776-0942
      from 8 AM - 10 PM ET

  • Send a Release
  • Sign Up
  • Log In
  • Resources
  • Blog
  • Journalists
  • RSS
  • GDPR
  • News in Focus
    • Browse All News
    • Multimedia Gallery
    • Trending Topics
  • Business & Money
    • Auto & Transportation
    • Business Technology
    • Entertain­ment & Media
    • Financial Services & Investing
    • General Business
  • Science & Tech
    • Consumer Technology
    • Energy & Natural Resources
    • Environ­ment
    • Heavy Industry & Manufacturing
    • Telecomm­unications
  • Lifestyle & Health
    • Consumer Products & Retail
    • Entertain­ment & Media
    • Health
    • Sports
    • Travel
  • Policy & Public Interest
  • People & Culture
    • People & Culture
  • Send a Release
  • Sign Up
  • Log In
  • Resources
  • Blog
  • Journalists
  • RSS
  • GDPR
  • Overview
  • Distribution by PR Newswire
  • Cision Communications Cloud®
  • Cision IR
  • All Products
  • Send a Release
  • Sign Up
  • Log In
  • Resources
  • Blog
  • Journalists
  • RSS
  • GDPR
  • General Inquiries
  • Request a Demo
  • Editorial Bureaus
  • Partnerships
  • Media Inquiries
  • Worldwide Offices
  • Send a Release
  • Sign Up
  • Log In
  • Resources
  • Blog
  • Journalists
  • RSS
  • GDPR

PAREXEL International Reports Third Quarter Fiscal Year 2015 Results

- Gross new business wins of $942.4 million, up 20.6% year-over-year; net book-to-bill ratio of 1.30; backlog at $5.19 billion

- 2.0% growth in consolidated service revenue to $502.0 million; 5.1% constant currency revenue growth

- SG&A as a percent of revenue decreased by 200 basis points year-over-year

- GAAP and adjusted operating margin of 10.8%; EBITA margin of 11.7%

- GAAP diluted earnings per share of $0.68 grew 13.3%; adjusted diluted earnings per share of $0.66 grew 17.9%


News provided by

PAREXEL International Corporation

Apr 29, 2015, 04:02 ET

Share this article

Share this article


BOSTON, April 29, 2015 /PRNewswire/ -- PAREXEL International Corporation (NASDAQ: PRXL) today reported financial results for the third quarter of Fiscal Year 2015, which ended on March 31, 2015. 

Mr. Josef H. von Rickenbach, PAREXEL's Chairman and Chief Executive Officer, stated "Benefits from our ongoing operational initiatives combined with improvements in our tax rate helped us to achieve our earnings per share target in the third quarter.  For the first nine months of this Fiscal Year, the operating margin has increased by approximately 100 basis points on a year-over-year basis.  PAREXEL Consulting experienced some client delays on a couple of large projects which negatively impacted third quarter revenue.  Those projects have now started to ramp up, and we expect that revenue growth in our PAREXEL Consulting business will be back on track in the fourth quarter on a sequential basis.  Revenue in our Clinical Research Services and PAREXEL Informatics businesses came in as we expected in the third quarter.  On the new business front, wins for the Company overall were very healthy, led by a strong performance in strategic accounts."

Mr. von Rickenbach continued, "As we enter the last quarter of our fiscal year, we believe we have positive underlying momentum in our businesses.  We expect revenue growth to improve on a sequential basis in the fourth quarter, as multiple projects begin to migrate out of start-up and into higher revenue generating stages.  We anticipate that the increased headcount will help us to achieve our goals in the fourth quarter and beyond.  I am pleased with our potential to increase the revenue growth rate in the second half of Calendar Year 2015.  We continue to be excited about the market opportunities that are in front of us, driven both by strategic partnerships and mid and small client companies, and we believe that we are well positioned to capitalize on them."

Third Quarter Fiscal Year 2015 Results
For the three months ended March 31, 2015 PAREXEL's consolidated service revenue increased by 2.0% to $502.0 million compared with $492.4 million in the prior year period.  Revenue grew 5.1% on a constant currency basis, excluding the negative impact of foreign currency exchange rate movements of $15.4 million.  Operating income as reported under Generally Accepted Accounting Principles (GAAP) totaled $54.2 million, or 10.8% of service revenue, in the third quarter of Fiscal Year 2015, as compared with $52.2 million, or 10.6% of service revenue, in the comparable quarter of the prior year.  GAAP net income for the quarter totaled $37.7 million, or $0.68 per diluted share, compared with GAAP net income of $34.7 million, or $0.60 per diluted share for the quarter ended March 31, 2014.  GAAP diluted earnings per share grew 13.3% year-over-year.

The financial results of the March quarter in the current and prior year period each included items outside of the Company's normal operations, as detailed in the financial charts within this press release.  Adjusted operating income in the third quarter of Fiscal Year 2015 was $54.1 million, or 10.8% of service revenue.  Adjusted operating income in the third quarter of Fiscal Year 2014 was $53.2 million, or 10.8% of service revenue.  Adjusted net income was $36.9 million, or $0.66 per diluted share in the quarter ended March 31, 2015, and was $32.3 million, or $0.56 per diluted share in the quarter ended March 31, 2014.  Adjusted diluted earnings per share grew 17.9% year-over-year.

On a segment basis, service revenue for the third quarter of Fiscal Year 2015 was $384.8 million in Clinical Research Services (CRS), $50.1 million in PAREXEL Consulting (PC), and $67.2 million in PAREXEL Informatics (PI). 

Nine Month Fiscal Year 2015 Results

For the nine months ended March 31, 2015, consolidated service revenue was $1.493 billion versus $1.429 billion in the prior year period, an increase of 4.5%.  GAAP operating income for the current nine-month period was $160.6 million, or 10.8% of service revenue, compared with GAAP operating income of $140.7 million, or 9.8% of service revenue in the prior year period.  GAAP net income for the nine months ended March 31, 2015 was $113.6 million, or $2.04 per diluted share, compared with GAAP net income of $89.0 million, or $1.55 per diluted share, in the prior year period.  GAAP diluted earnings per share grew 31.6% year-over-year.

Excluding the impact of special items in both nine month periods, as detailed in the attached financial charts, adjusted operating income was $159.9 million or 10.7% of consolidated service revenue for the nine months ended on March 31, 2015, compared with $142.9 million or 10.0% of consolidated service revenue for the nine months ended on March 31, 2014.  Adjusted net income for the nine months ended March 31, 2015 was $111.6 million, or $2.00 per diluted share, compared with $87.3 million or $1.52 per diluted share in the comparable prior year nine month period.  Adjusted diluted earnings per share grew 31.6% year-over-year.

New Business and Backlog
Backlog at the end of March 2015 was $5.19 billion, an increase of 5.3% year-over-year.  The reported backlog included gross new business wins in the third quarter of $942.4 million, cancellations of $289.7 million, and a negative impact from foreign currency exchange rates of $62.3 million. The net book-to-bill ratio was 1.30 in the quarter, and the trailing twelve month net book-to-bill ratio was 1.22.

Forward-looking Guidance
The Company issued forward-looking guidance for the fourth quarter (ending June 30, 2015) and for Fiscal Year 2015 in its entirety as detailed in the chart below.  The guidance takes into account a number of factors, including the results of the third quarter, recent foreign currency exchange rates, tax rates, recent acquisitions, and the Company's updated overall outlook. 


Guidance Issued 4/29/15

Guidance Issued 1/28/15

Q4 FY 2015 Revenue

$520 - $540 million

N/A

Q4 FY 2015 GAAP EPS

$0.65 - $0.81

N/A




FY 2015 Revenue

$2.012 - $2.032 billion

$2.040 - $2.070 billion

FY 2015 GAAP EPS

FY 2015 Non-GAAP EPS

$2.68 - $2.86

$2.65 - $2.83

$2.68 - $2.86

$2.65 - $2.83

Additional Information
In addition to the financial measures prepared in accordance with GAAP, the Company uses certain non-GAAP financial measures.  The Company believes that presenting the non-GAAP financial measures contained in this press release assists investors and others in gaining a better understanding of its core operating results and future prospects, especially when comparing such results to previous periods or forecasted guidance, because such measures exclude items that are outside of the Company's normal operations and/or, in certain cases, are difficult to forecast accurately for future periods.  Management uses non-GAAP financial measures, in addition to the measures prepared in accordance with GAAP, as the basis for measuring the Company's core operating performance and comparing such performance to that of prior periods and to the performance of its competitors for the same reasons stated above.  Such measures are also used by management in its financial and operating decision-making.  Non-GAAP financial measures should not be considered superior to nor a substitute for the Company's results of operations prepared in accordance with GAAP.

A conference call to discuss PAREXEL's Third Quarter Fiscal Year 2015 earnings, business, and financial outlook will begin at 10:00 a.m. ET on Thursday, April 30, 2015 and will be broadcast live over the internet via webcast.  The webcast may be accessed in the "IR Calendar" portion of the main page of the Investors section of the Company's website at www.PAREXEL.com.   Users should follow the instructions provided to assure that the necessary audio applications are downloaded and installed.  A replay of this webcast will be archived on the website approximately two hours after the call and will continue to be accessible for approximately one year following the live event.  To participate via telephone, dial +1 (408) 940-3886 and ask to join the PAREXEL International Third Quarter Fiscal Year 2015 earnings conference call.

A presentation of Third Quarter Fiscal Year 2015 results, as well as certain trended financial information, may be found on the home page of the Investors section of the Company's website in a document titled "Q3 Financial Results and Trended Information".

About PAREXEL International

PAREXEL International Corporation is a leading global biopharmaceutical services organization, providing a broad range of expertise-based contract research, consulting, medical communications, and technology solutions and services to the worldwide pharmaceutical, biotechnology and medical device industries. Committed to providing solutions that expedite time-to-market and peak-market penetration, PAREXEL has developed significant expertise across the development and commercialization continuum, from drug development and regulatory consulting to clinical pharmacology, clinical trials management, medical education and reimbursement. PAREXEL Informatics, Inc. provides advanced technology solutions, including medical imaging, to facilitate the clinical development process. Headquartered near Boston, Massachusetts, PAREXEL operates in 80 locations in 51 countries around the world, and had approximately 17,440 employees in the third quarter.  For more information about PAREXEL International visit www.PAREXEL.com.

PAREXEL and PAREXEL Informatics are trademarks or registered trademarks of PAREXEL International Corporation or its affiliates.

This release contains "forward-looking" statements regarding future results and events, including, without limitation, statements regarding expected financial results, future growth and customer demand.   For this purpose, any statements contained herein that are not statements of historical fact may be deemed forward-looking statements.  Without limiting the foregoing, the words "believes," "anticipates," "plans," "expects," "intends," "appears," "estimates," "projects," "will," "would," "could," "should,"  "targets," and similar expressions are also intended to identify forward-looking statements.  The forward-looking statements in this release involve a number of risks and uncertainties.  The Company's actual future results may differ materially from the results discussed in the forward-looking statements contained in this release.  Important factors that might cause such a difference include, but are not limited to, risks associated with: actual operating performance; actual expense savings and other operating improvements resulting from restructurings; the loss, modification, or delay of contracts which would, among other things, adversely impact the Company's recognition of revenue included in backlog; the Company's dependence on certain industries and clients; the Company's ability to win new business, manage growth and costs, and attract and retain employees; the Company's ability to complete additional acquisitions, and to integrate newly acquired businesses including the acquisitions of ClinIntel Limited and Quantum Solutions India, or enter into new lines of business; the impact on the Company's business of government regulation of the drug,  medical device and biotechnology industry; consolidation within the pharmaceutical industry and competition within the biopharmaceutical services industry; the potential for significant liability to clients and third parties; the potential adverse impact of health care reform; and the effects of foreign currency exchange rate fluctuations and other international economic, political, and other risks.   Such factors and others are discussed more fully in the section entitled "Risk Factors" of the Company's Quarterly Report on Form 10-Q for the quarter ended December 31, 2014 as filed with the Securities and Exchange Commission on February 5, 2015, which "Risk Factors" discussion is incorporated by reference in this press release.  The Company specifically disclaims any obligation to update these forward-looking statements in the future.  These forward-looking statements should not be relied upon as representing the Company's estimates or views as of any date subsequent to the date of this press release.

CONTACTS:

Ingo Bank, Senior Vice President and Chief Financial Officer


Jill Baker, Corporate Vice President of Investor Relations


+1-781-434-4118

PAREXEL International Corporation

 Consolidated Condensed Statement of Operations

(Unaudited)


























Three Months Ended


Nine Months Ended


(in thousands, except per share data)


March 31, 2015


March 31, 2014


March 31, 2015


March 31, 2014













Service revenue



$                     502,033


$                      492,375


$                   1,492,998


$                   1,428,765


Reimbursement revenue



74,382


85,543


232,151


252,453


Total revenue



576,415


577,918


1,725,149


1,681,218













Costs and expenses:











Direct costs



337,954


323,149


984,094


950,850


Reimbursable out-of-pocket expenses


74,382


85,543


232,151


252,453


Selling, general and administrative


88,427


96,528


286,135


276,968


Depreciation



17,934


16,802


51,644


48,848


Amortization



3,489


3,725


10,532


11,383


Total costs and expenses



522,186


525,747


1,564,556


1,540,502













Income from operations



54,229


52,171


160,593


140,716













Interest expense, net



(1,820)


(2,072)


(5,392)


(7,342)


Miscellaneous income (expense)



1,314


(292)


7,594


(1,694)


Other income (expense), net



(506)


(2,364)


2,202


(9,036)













Income before income taxes



53,723


49,807


162,795


131,680













Provision for income taxes



15,982


15,068


49,152


42,658


Effective tax rate



29.7%


30.3%


30.2%


32.4%













Net income



$                        37,741


$                        34,739


$                      113,643


$                        89,022













Earnings per common share:











Basic



$0.69


$0.61


$2.07


$1.58


Diluted



$0.68


$0.60


$2.04


$1.55













Shares used in computing earnings per common share:








Basic



54,930


56,713


54,830


56,494


Diluted



55,838


57,673


55,769


57,486
























Balance Sheet Information



Preliminary











March 31, 2015


March 31, 2014


June 30, 2014




Billed accounts receivable, net



$                      447,302


$                      522,850


$                      497,108




Unbilled accounts receivable, net



258,439


229,019


$                      225,514




Deferred revenue



(423,042)


(494,782)


$                    (466,964)




Net receivables



$                      282,699


$                      257,087


$                      255,658















Cash and marketable securities



$                      295,351


$                      298,655


$                      283,812




Working capital



$                      447,129


$                      397,085


$                      350,900




Total assets



$                   1,798,809


$                   1,873,285


$                   1,834,000




Short-term borrowings



$                          5,000


$                        10,533


$                        12,501




Long-term debt



$                      380,000


$                      290,000


$                      337,500




Stockholders' equity



$                      603,763


$                      670,764


$                      577,681




PAREXEL International Corporation

  Reconciliation of Non-GAAP Measures

Certain Line Items

(Unaudited)





























Three Months Ended


Three Months Ended

(in thousands, except per share data)

March 31, 2015


March 31, 2014




GAAP
Measure


Adjustments


Non-GAAP Measure


GAAP Measure


Adjustments


Non-GAAP Measure














Selling, general and administrative 


$           88,427


$               91

(a)

$        88,518


$        96,528


$         (1,010)

(a)

$        95,518














Income from operations


$           54,229


$             (91)


$        54,138


$        52,171


$          1,010


$        53,181














Other expense, net


$               (506)


$                -


$            (506)


$         (2,364)


$            (196)

(c)

$         (2,560)














Income before income taxes


$           53,723


$             (91)


$        53,632


$        49,807


$              814


$        50,621














Provision for income taxes


$           15,982


$            760

(b)

$        16,742


$        15,068


$          3,210

(d)

$        18,278














Net income


$           37,741


$           (851)


$        36,890


$        34,739


$         (2,396)


$        32,343














Diluted earnings per common share


$                0.68


$          (0.02)


$             0.66


$             0.60


$           (0.04)


$             0.56














Effective tax rate


29.7%




31.2%


30.3%




36.1%



























(a) Impact of net adjustments for legal settlements and acquisition and integration related charges, including the revaluation of earn-out
contingent consideration liability associated with certain acquisitions.

(b) Tax effect on non-GAAP adjustments













(c) Recovery from bankruptcy settlement on previously impaired investment

(d) Tax effect on non-GAAP adjustments, and a $3.0 million adjustment due to reserve release







PAREXEL International Corporation

  Reconciliation of Non-GAAP Measures

Certain Line Items

(Unaudited)
































Nine Months Ended


Nine Months Ended

(in thousands, except per share data)


March 31, 2015


March 31, 2014




GAAP Measure


Adjustments


Non-GAAP Measure


GAAP Measure


Adjustments


Non-GAAP Measure















Selling, general and administrative 



$   286,135


$            649

(a)

$      286,784


$      276,968


$         (2,162)

(a)

$      274,806















Income from operations



$   160,593


$           (649)


$      159,944


$      140,716


$          2,162


$      142,878















Other income (expense), net



$        2,202


$            137

(b)

$          2,339


$         (9,036)


$            (196)

(d)

$         (9,232)















Income before income taxes



$   162,795


$           (512)


$      162,283


$      131,680


$          1,966


$      133,646















Provision for income taxes



$     49,152


$         1,557

(c)

$        50,709


$        42,658


$          3,685

(e)

$        46,343















Net income



$   113,643


$       (2,069)


$      111,574


$        89,022


$         (1,719)


$        87,303















Diluted earnings per common share



$          2.04


$          (0.04)


$             2.00


$             1.55


$           (0.03)


$             1.52















Effective tax rate



30.2%




31.2%


32.4%




34.7%





























(a) Impact of net adjustments for legal settlements and acquisition and integration related charges, including the revaluation of earn-out
contingent consideration liability associated with certain acquisitions.

(b) Accelerated amortization of deferred financing fees related to credit facility modification

(c) Tax effect on non-GAAP adjustments

(d) Recovery from bankruptcy settlement on previously impaired investment

(e) Tax effect on non-GAAP adjustments, and a $3.0 million adjustment due to reserve release

PAREXEL International Corporation


Segment Information


(Unaudited)




















Three Months Ended


Three Months Ended


(in thousands)


March 31, 2015


March 31, 2014










Clinical Research Services (CRS)
















Service revenue 


$                           384,779



$                           373,216



% of total service revenue


76.6%



75.8%



Gross profit


$                           110,726



$                           117,972



Gross margin % of service revenue


28.8%



31.6%











PAREXEL Consulting Services (PC)
















Service revenue


$                             50,070



$                             55,302

(a)


% of total service revenue


10.0%



11.2%



Gross profit


$                             21,425



$                             22,469

(a)


Gross margin % of service revenue


42.8%



40.6%



















PAREXEL Informatics (PI)
















Service revenue


$                             67,184



$                             63,857

(a)


% of total service revenue


13.4%



13.0%



Gross profit


$                             31,928



$                             28,785

(a)


Gross margin % of service revenue


47.5%



45.1%



















Total service revenue


$                           502,033



$                           492,375



Total gross profit


$                           164,079



$                           169,226



Gross margin % of service revenue


32.7%



34.4%



















Quarterly Supplemental Financial Data
















Service revenue


$                           502,033



$                           492,375



Reimbursement revenue


74,382



85,543



Investigator fees


101,232



120,796



Gross revenue


$                           677,647



$                           698,714











Days sales outstanding


38



33











Capital expenditures


$                             21,998



$                             15,636











(a) Effective July 1, 2014, the operating results of PAREXEL Regulatory Outsourcing Services are included in the PC segment. This service line offering was previously reported within the PI segment. For the three months ended March 31, 2015 and 2014, we disclosed the reportable segment on this basis and the prior period was retroactively restated to reflect this presentation change.


PAREXEL International Corporation


Segment Information



(Unaudited)



























Nine Months Ended



Nine Months Ended



(in thousands)


March 31, 2015



March 31, 2014














Clinical Research Services (CRS)






















Service revenue 


$                        1,131,994



$                        1,069,675






% of total service revenue


75.8%



74.9%






Gross profit


$                           340,576



$                           321,012






Gross margin % of service revenue


30.1%



30.0%

















PAREXEL Consulting Services (PC)






















Service revenue


$                           162,495



$                           171,523

(a)




% of total service revenue


10.9%



12.0%






Gross profit


$                             71,735



$                             70,060

(a)




Gross margin % of service revenue


44.1%



40.8%




























PAREXEL Informatics (PI)






















Service revenue


$                           198,509



$                           187,567

(a)




% of total service revenue


13.3%



13.1%






Gross profit


$                             96,593



$                             86,843

(a)




Gross margin % of service revenue


48.7%



46.3%




























Total service revenue


$                        1,492,998



$                        1,428,765






Total gross profit


$                           508,904



$                           477,915






Gross margin % of service revenue


34.1%



33.4%




























(a) Effective July 1, 2014, the operating results of PAREXEL Regulatory Outsourcing Services are included in the PC segment. This service line offering was previously reported within the PI segment. For the nine months ended March 31, 2015 and 2014, we disclosed the reportable segment on this basis and the prior period was retroactively restated to reflect this presentation change. 





SOURCE PAREXEL International Corporation

Related Links

http://www.parexel.com

Modal title

Contact Cision

  • Cision Distribution 888-776-0942
    from 8 AM - 9 PM ET

  • Chat with an Expert
  • General Inquiries
  • Request a Demo
  • Editorial Bureaus
  • Partnerships
  • Media Inquiries
  • Worldwide Offices

Products

  • Cision Communication Cloud®
  • For Marketers
  • For Public Relations
  • For IR & Compliance
  • For Agency
  • For Small Business
  • All Products

About

  • About PR Newswire
  • About Cision
  • Become a Publishing Partner
  • Become a Channel Partner
  • Careers
  • COVID-19 Resources
  • Accessibility Statement
  • Asia
  • Brazil
  • Canada
  • Czech
  • Denmark
  • Finland
  • France
  • Germany
  • India
  • Israel
  • Italy
  • Mexico
  • Middle East
  • Netherlands
  • Norway
  • Poland
  • Portugal
  • Russia
  • Slovakia
  • Spain
  • Sweden
  • United Kingdom

My Services

  • All New Releases
  • Online Member Center
  • ProfNet

Contact Cision

Products

About

My Services
  • All News Releases
  • Online Member Center
  • ProfNet
Cision Distribution Helpline
888-776-0942
  • Terms of Use
  • Privacy Policy
  • Information Security Policy
  • Site Map
  • RSS
  • Cookie Settings
Copyright © 2022 Cision US Inc.